BIO-PATH HOLDINGS, INC. SEC 10-Q Report

Bio-Path Holdings, Inc., a clinical and preclinical stage oncology and obesity-focused RNAi nanoparticle drug development company, has released its Form 10-Q report for the second quarter of 2025. The report provides a detailed overview of the company's financial performance and operational activities, including updates on its drug development programs and strategic initiatives.

Financial Highlights

• Revenue: $0 million. The company did not generate any revenue for the three and six months ended June 30, 2025, and 2024.
• Net Operating Loss: $4.6 million for the three months ended June 30, 2025, an increase of $1.5 million compared to the three months ended June 30, 2024.
• Net Operating Loss: $7.8 million for the six months ended June 30, 2025, a decrease of $1.1 million compared to the six months ended June 30, 2024.
• Net Loss: $4.6 million for the three months ended June 30, 2025, an increase of $2.7 million compared to the three months ended June 30, 2024.
• Net Loss: $7.4 million for the six months ended June 30, 2025, a decrease of $2.4 million compared to the six months ended June 30, 2024.
• Net Loss per Share: $0.55 for the three months ended June 30, 2025, compared to $1.16 for the three months ended June 30, 2024.
• Net Loss per Share: $0.97 for the six months ended June 30, 2025, compared to $4.45 for the six months ended June 30, 2024.

Business Highlights

• Business Overview: Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology and obesity-focused RNAi nanoparticle drug development company. The company utilizes a novel technology called DNAbilize® for systemic delivery of antisense drug substances targeting over-expressed gene products in diseases.
• Product Development: The company has four drug candidates in development targeting at least five different cancer indications and one obesity indication. The lead drug candidate, prexigebersen, is in a Phase 2 clinical trial for AML patients.
• Clinical Trials: The Phase 2 clinical trial for prexigebersen includes three cohorts, with the first two cohorts showing promising interim results. The trial is being conducted at multiple sites in the U.S., with Dr. Gail J. Roboz as the national coordinating Principal Investigator.
• Research and Development Focus: The company is focusing on developing drug candidates for cancer and obesity, with ongoing clinical trials and preclinical studies. The company is also developing a molecular biomarker package to enhance the probability of success for its programs.
• Operational Pause: As of June 24, 2025, Bio-Path Holdings announced an operational pause to conserve capital, furloughing most employees and pausing operations while seeking additional financing.
• Future Outlook: The company expects to continue incurring significant operating expenses related to clinical trials, manufacturing, and regulatory approval processes. It is actively seeking additional capital to fund its operations and continue its drug development programs.

SEC Filing: BIO-PATH HOLDINGS, INC. [ BPTH ] - 10-Q - Aug. 14, 2025